Saltar al contenido
Merck

Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam.

Therapeutic drug monitoring (2006-06-17)
Yukihiro Ujiie, Takashi Fukasawa, Norio Yasui-Furukori, Akihito Suzuki, Tomonori Tateishi, Koichi Otani
RESUMEN

The purpose of the present study was to examine the effects of rifampicin on the single oral dose pharmacokinetics and pharmacodynamics of brotizolam. Thirteen healthy male volunteers received rifampicin 450 mg/day, or matched placebo, for 7 days in a double-blind randomized crossover manner. On the sixth day they received a single oral 0.5-mg dose of brotizolam, and blood sampling was performed for 24 hours, together with an assessment of psychomotor function using the Digit Symbol Substitution Test and the Stanford Sleepiness Scale. Rifampicin treatment significantly (P<0.001) decreased the peak plasma concentration (69%), total area under the plasma concentration-time curve (90%) and elimination half-life (79%) of brotizolam. Rifampicin significantly increased the area under the score-time curve of the Digit Symbol Substitution Test (P<0.01), and decreased that of the Stanford Sleepiness Scale (P<0.05). The present study suggests that rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam and, therefore, this combination is not recommended in clinical practice.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Brotizolam, European Pharmacopoeia (EP) Reference Standard